Cargando…

Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies

Cancer and cardiovascular diseases are the leading causes of death and morbidity worldwide. Strikingly, cardiovascular disorders are more common and more severe in cancer patients than in the general population, increasing incidence rates. In this context, it is vital to consider the anticancer effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Borges, Gabriel Silva Marques, Lages, Eduardo Burgarelli, Sicard, Pierre, Ferreira, Lucas Antônio Miranda, Richard, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277942/
https://www.ncbi.nlm.nih.gov/pubmed/34277738
http://dx.doi.org/10.3389/fcvm.2021.690533
_version_ 1783722160644161536
author Borges, Gabriel Silva Marques
Lages, Eduardo Burgarelli
Sicard, Pierre
Ferreira, Lucas Antônio Miranda
Richard, Sylvain
author_facet Borges, Gabriel Silva Marques
Lages, Eduardo Burgarelli
Sicard, Pierre
Ferreira, Lucas Antônio Miranda
Richard, Sylvain
author_sort Borges, Gabriel Silva Marques
collection PubMed
description Cancer and cardiovascular diseases are the leading causes of death and morbidity worldwide. Strikingly, cardiovascular disorders are more common and more severe in cancer patients than in the general population, increasing incidence rates. In this context, it is vital to consider the anticancer efficacy of a treatment and the devastating heart complications it could potentially cause. Oncocardiology has emerged as a promising medical and scientific field addressing these aspects from different angles. Interestingly, nanomedicine appears to have great promise in reducing the cardiotoxicity of anticancer drugs, maintaining or even enhancing their efficacy. Several studies have shown the benefits of nanocarriers, although with some flaws when considering the concept of oncocardiology. Herein, we discuss how preclinical studies should be designed as closely as possible to clinical protocols, considering various parameters intrinsic to the animal models used and the experimental protocols. The sex and age of the animals, the size and location of the tumors, the doses of the nanoformulations administered, and the acute vs. the long-term effects of treatments are essential aspects. We also discuss the perspectives offered by non-invasive imaging techniques to simultaneously assess both the anticancer effects of treatment and its potential impact on the heart. The overall objective is to accelerate the development and validation of nanoformulations through high-quality preclinical studies reproducing the clinical conditions.
format Online
Article
Text
id pubmed-8277942
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82779422021-07-15 Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies Borges, Gabriel Silva Marques Lages, Eduardo Burgarelli Sicard, Pierre Ferreira, Lucas Antônio Miranda Richard, Sylvain Front Cardiovasc Med Cardiovascular Medicine Cancer and cardiovascular diseases are the leading causes of death and morbidity worldwide. Strikingly, cardiovascular disorders are more common and more severe in cancer patients than in the general population, increasing incidence rates. In this context, it is vital to consider the anticancer efficacy of a treatment and the devastating heart complications it could potentially cause. Oncocardiology has emerged as a promising medical and scientific field addressing these aspects from different angles. Interestingly, nanomedicine appears to have great promise in reducing the cardiotoxicity of anticancer drugs, maintaining or even enhancing their efficacy. Several studies have shown the benefits of nanocarriers, although with some flaws when considering the concept of oncocardiology. Herein, we discuss how preclinical studies should be designed as closely as possible to clinical protocols, considering various parameters intrinsic to the animal models used and the experimental protocols. The sex and age of the animals, the size and location of the tumors, the doses of the nanoformulations administered, and the acute vs. the long-term effects of treatments are essential aspects. We also discuss the perspectives offered by non-invasive imaging techniques to simultaneously assess both the anticancer effects of treatment and its potential impact on the heart. The overall objective is to accelerate the development and validation of nanoformulations through high-quality preclinical studies reproducing the clinical conditions. Frontiers Media S.A. 2021-06-30 /pmc/articles/PMC8277942/ /pubmed/34277738 http://dx.doi.org/10.3389/fcvm.2021.690533 Text en Copyright © 2021 Borges, Lages, Sicard, Ferreira and Richard. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Borges, Gabriel Silva Marques
Lages, Eduardo Burgarelli
Sicard, Pierre
Ferreira, Lucas Antônio Miranda
Richard, Sylvain
Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies
title Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies
title_full Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies
title_fullStr Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies
title_full_unstemmed Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies
title_short Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies
title_sort nanomedicine in oncocardiology: contribution and perspectives of preclinical studies
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277942/
https://www.ncbi.nlm.nih.gov/pubmed/34277738
http://dx.doi.org/10.3389/fcvm.2021.690533
work_keys_str_mv AT borgesgabrielsilvamarques nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies
AT lageseduardoburgarelli nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies
AT sicardpierre nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies
AT ferreiralucasantoniomiranda nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies
AT richardsylvain nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies